Biogen Reiterates Byooviz Will Not Be Meaningful In 2022
Launches Outside Of The US Scheduled For Early 2023
Executive Summary
Biogen is looking for its ranibizumab biosimilar Byooviz to make a splash in 2023 as it continues to forecast falling biosimilars sales for 2022.
You may also be interested in...
Coherus Shakes Up Ranibizumab Competition With First Interchangeable US Biosimilar
Coherus BioSciences has heralded a “strategic inflection point” for the company after receiving USFDA approval for Cimerli as an interchangeable biosimilar rival to Lucentis. The firm has also revealed launch plans for the Bioeq-partnered ranibizumab product.
Biogen and Bio-Thera Report Progress On Tocilizumab
Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.
Biogen Exits Joint Venture As Samsung Biologics Buys Out Bioepis
Biogen’s stake in Samsung Bioepis has been fully acquired by former partner Samsung Biologics, following an announcement of the deal in January.